Effect of Hepatosteatosis on the Virological Response in Entecavir and Tenofovir Therapies

Date
2019
Author
Tuncer-Ertem, Gunay
Yuksel, Esma
Hakyemez, Ismail Necati
MERİÇ KOÇ, MELİHA
Cinar, Gule
TOKA, ONUR
Yoruk, Gulsen
Ataman-Hatipoglu, Cigdem
Sarigul, Figen
SIRMATEL, FATMA
Imre, Ayfer
MISTANOĞLU ÖZATAĞ, DURU
KARAKEÇİLİ, FARUK
URAL, ONUR
SÜMER, ŞUA
Aktug-Demir, Nazlim
Kadanali, Ayten
Ucer, Sengul
Gunal, Ozgur
Ozkaya, Hacer Deniz
Yenilmez, Ercan
Cetinkaya, Riza Aytac
Celik, Ilhami
YILMAZ, EMEL
Evik, Guliz
Kaya, Ali
Suer, Kaya
Saltoglu, Nese
Comoglu, Senol
KORKMAZ, PINAR
Demirturk, Nese
Batirel, Ayse
Tulek, Necla
Ozguler, Muge
Harman, Rezan
Bestepe-Dursun, Zehra
Metadata
Show full item record
Abstract
Objective: Both chronic hepatitis B (CHB) and hepatosteatosis may lead to necroinflammation in liver. Therefore, the presence of hepatosteatosis might negatively affect the efficacy of antiviral therapy. We aimed to determine the effect of hepatosteatosis on virological response in patients with CHB receiving entecavir (ETV) and tenofovir (TDF) treatment.
URI
http://hdl.handle.net/20.500.12627/24410
https://doi.org/10.5152/kd.2019.73
Collections